血管内碎石术用于左主干严重钙化病变的可行性、安全性与疗效
这项前瞻性、多中心、开放标签研究纳入 50 例梗阻性左主干远端病变且 IVUS 证实环形钙化的患者,评估 IVL 辅助 PCI 的可行性与安全性。结果显示所有病例均成功通过器械,左主干平均最小支架面积为 13.36 ± 3.20 mm²,30 天无 MACE 事件。12 个月 MACE 发生率为 8.0%,无支架血栓形成。
要点
- IVL 辅助 PCI 可用于左主干远端严重钙化病变的钙化修饰。
- 左主干平均最小支架面积达 13.36 mm²,84% 患者超过 11 mm²。
- 30 天无 MACE,12 个月 MACE 发生率为 8.0% 且无支架血栓。
核心结论
- 对于严重钙化的左主干远端病变,IVL 用于钙化修饰是安全且机械有效的。
研究设计与样本
- 前瞻性、多中心、开放标签研究,在英国 5 个中心开展,纳入 50 例梗阻性左主干远端病变且 IVUS 确认至少一个节段最大钙化弧度 ≥ 270° 的患者。
主要发现
- 50 例患者均成功完成器械通过,左主干平均最小支架面积为 13.36 ± 3.20 mm²(95% CI 12.44–14.28 mm²)。
- 84% 的患者(41/49)左主干最小支架面积超过 11 mm²。
- 所有区域均观察到显著的管腔获得,左主干为 7.19 ± 3.52 mm²(p < 0.001)。
- IVUS 可见的钙化断裂与支架扩张无相关性。
- 30 天内无围术期死亡或心肌梗死,无 MACE 事件。
关键数值与推荐
- 主要共同终点为 IVUS 评估的最小支架面积和 30 天 MACE。
- IVUS 在预处理、IVL 后和支架置入后三个时间点强制实施,并由独立核心实验室分析。
临床怎么用
- 对 IVUS 确认存在环形钙化的左主干远端病变,可考虑 IVL 辅助 PCI 进行钙化修饰。
局限性
- 研究未设对照组,样本量为 50 例,12 个月随访事件数较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Background IVL is increasingly used for coronary calcium modification; however, prospective data for its use in LMS lesions are lacking. Aims To evaluate the feasibility, safety, and mechanical efficacy of intravascular lithotripsy (IVL) for calcium modification in calcified distal left main stem (LMS) percutaneous coronary intervention. Methods In this prospective, multicentre, open-label study across five United Kingdom centers (NCT04319666), 50 patients with obstructive distal LMS disease and IVUS-confirmed circumferential calcification (maximum calcium arc ≥ 270° in at least one segment) underwent IVL-assisted PCI. IVUS was mandated at pre-treatment, post-IVL, and post-stent timepoints with independent core laboratory analysis. Co-primary endpoints were IVUS-assessed minimum stent area (MSA) and 30-day major adverse cardiac events (MACE). Results Fifty patients underwent IVUS-guided LMS PCI with IVL for calcium modification. Device crossing was successful in all 50 cases. Mean LMS MSA was 13.36 ± 3.20 mm2 (95% CI 12.44–14.28 mm2); 84% of patients (41/49) achieved an LMS MSA exceeding 11 mm2. Significant luminal gain was observed across all territories (LMS 7.19 ± 3.52 mm2, p < 0.001). IVUS-visible calcium fracture was not associated with stent expansion. There were no periprocedural deaths or myocardial infarctions and no MACE at 30 days. At 12 months, MACE occurred in 4 patients (8.0%) with no stent thrombosis. Conclusions IVL is safe and mechanically efficacious for calcium modification in severely calcified distal LMS disease, achieving stent expansion exceeding prognostically validated thresholds with favorable clinical outcomes at 12 months. Clinical trial registration clinicaltrials.gov NCT04319666.
引用
- Catheterization and Cardiovascular Interventions:Intravascular Lithotripsy in Left Main Stem Percutaneous Coronary Intervention
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。